GlassScriptPhysician profile
Sarah E Elkin
NPI 1114440625
$1,288.19
in general payments reported to CMS, 2019-2025
22 companies · $688 in 2025
The $688 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.68 · 2022: $112 · 2023: $291 · 2024: $157 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,136.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $237.60 | 2022-2023 | |
| Incyte Corporation | $124.03 | 2025 | Niktimvo |
| Jazz Pharmaceuticals INC. | $121.75 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $119.47 | 2024-2025 | Prevymis |
| Sobi, INC | $89.14 | 2025 | |
| Novartis Pharmaceuticals Corporation | $79.77 | 2023 | |
| Pfizer INC. | $56.30 | 2025 | |
| Novo Nordisk INC | $54.20 | 2023-2025 | Alhemo |
| Emmaus Medical, INC. | $50.87 | 2025 | Endari |
| Rare Disease Therapeutics, INC. | $43.01 | 2025 | Xromi |
| Bayer Healthcare Pharmaceuticals INC. | $42.11 | 2025 | |
| Abbvie INC. | $38.86 | 2025 | |
| Csl Behring | $33.50 | 2024 | Idelvion |
| Chiesi USA, INC. | $29.83 | 2024 | Ferriprox |
| Piramal Critical Care | $26.51 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mesoblast, INC. | $23.30 | 2025 | Ryoncil |
| Y-Mabs Therapeutics, INC. | $22.34 | 2023 | Danyelza |
| Celgene Corporation | $21.39 | 2025 | Breyanzi |
| Alexion Pharmaceuticals, INC. | $20.93 | 2024 | Ultomiris |
| Syndax Pharmaceuticals, INC. | $20.88 | 2025 | |
| Day One Biopharmaceuticals | $17.01 | 2025 | Ojemda |
| Agios Pharmaceuticals, INC. | $15.39 | 2024 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Elkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.